Clinical Trials

Leukemia, Myeloid, Acute

NCT04269902 2026-03-19

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Phase 3 Recruiting

247 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04439201 2026-03-19

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

40 enrolled 9 charts

Lymphoma, Hematologic Neoplasms

NCT04439318 2026-03-19

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

50 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05554419 2026-03-19

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

184 enrolled

Leukemia, Myeloid, Acute

NCT05621291 2026-03-19

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

Phase NA Recruiting

60 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06303167 2026-03-19

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

19 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06311227 2026-03-19

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

20 enrolled

Leukemia, Hairy Cell

NCT06514261 2026-03-19

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

45 enrolled

Leukemia, Myeloid, Acute

NCT06802523 2026-03-19

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Phase 1 Suspended

53 enrolled

Leukemia, Myeloid, Acute

NCT07437950 2026-03-19

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

126 enrolled

Leukemia, Myeloid, Acute

NCT00070499 2026-03-18

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

406 enrolled 11 charts

Phase 1/2 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00392353 2026-03-18

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

135 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00658814 2026-03-18

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

133 enrolled 10 charts

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00792948 2026-03-18

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

97 enrolled 7 charts

Phase 3 Active not recruiting

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00843882 2026-03-18

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

247 enrolled 19 charts

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01522976 2026-03-18

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Classical hematologyMyeloidOther hematologic neoplasm

282 enrolled 11 charts

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01627041 2026-03-18

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

178 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT01841723 2026-03-18

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

44 enrolled

Leukemia, Hairy Cell

NCT02143414 2026-03-18

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

53 enrolled 12 charts

Phase 3 Active not recruiting

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03701282 2026-03-18

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

720 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03816345 2026-03-18

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

300 enrolled

Phase 3 Active not recruiting

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

NCT03914625 2026-03-18

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

6,720 enrolled

Phase 1 Active not recruiting

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04190550 2026-03-18

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

24 enrolled

Leukemia, Myeloid, Acute

NCT04301076 2026-03-18

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

30 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmPlasma cellThoracic

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04314401 2026-03-18

National Cancer Institute "Cancer Moonshot Biobank"

Recruiting

1,600 enrolled

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04439292 2026-03-18

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

35 enrolled

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439331 2026-03-18

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-03-18

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05436418 2026-03-18

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase 1/2 Recruiting

260 enrolled

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05554393 2026-03-18

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

153 enrolled

Leukemia, Myeloid, Acute

NCT05554406 2026-03-18

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

335 enrolled

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-03-18

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05600894 2026-03-18

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Classical hematologyMyeloidOther hematologic neoplasm

132 enrolled

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT05886049 2026-03-18

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

28 enrolled

Acute Myeloid Leukemia With KMT2A Rearrangement

NCT05969002 2026-03-18

Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias

Completed

10 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06317649 2026-03-18

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

147 enrolled

Leukemia, Myeloid, Acute

NCT06317662 2026-03-18

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT06904066 2026-03-18

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

86 enrolled

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06954987 2026-03-18

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

244 enrolled

Leukemia, Myeloid, Acute

NCT06965114 2026-03-18

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Phase 1/2 Recruiting

84 enrolled

Leukemia, Hairy Cell

NCT07328503 2026-03-18

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

20 enrolled